Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20025
Título
SEOM Clinical guidelines for the treatment of metastatic prostate cancer
Autor(es)
Fecha de publicación
2014-12
Cita
Cassinello J, Climent MA, Gonzalez Del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014 Dec;16(12):1060-6. Epub 2014 Oct 16.
Idioma
Inglés
Tipo de documento
research article
Resumen
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.
Palabras clave
Androgen deprivation treatment | Castration-resistant prostate cancer | Docetaxel | Cabacitaxel | Abiraterone | Enzalutamide | Radium 223
MESH
DECS
Adenocarcinoma | Antineoplásicos | Humanos | Neoplasias de la Próstata | Masculino
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo